Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.

Autores:: Parra Medina, Rafael
Yaspe, Edgardo
Hernández, Diana
Sánchez, Diana Marcela
Marulanda, Lina
Polo, José Fernando

Tipo de recurso:: Article of journal

Fecha de publicación:: 2019

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_b2ed48bc6c3cab7e187956a87bd5979d
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2916
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
dc.title.translated.eng.fl_str_mv	Ovary and fallopian tube expression of p53 in primary epithelial ovarian cancer
title	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
spellingShingle	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario. Carcinoma de ovario Tumores tipo I-II p53 signature TP53 Ovary carcinoma Type I-II tumors p53 signature TP53
title_short	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
title_full	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
title_fullStr	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
title_full_unstemmed	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
title_sort	Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.
dc.creator.fl_str_mv	Parra Medina, Rafael Yaspe, Edgardo Hernández, Diana Sánchez, Diana Marcela Marulanda, Lina Polo, José Fernando
dc.contributor.author.spa.fl_str_mv	Parra Medina, Rafael Yaspe, Edgardo Hernández, Diana Sánchez, Diana Marcela Marulanda, Lina Polo, José Fernando
dc.subject.spa.fl_str_mv	Carcinoma de ovario Tumores tipo I-II p53 signature TP53
topic	Carcinoma de ovario Tumores tipo I-II p53 signature TP53 Ovary carcinoma Type I-II tumors p53 signature TP53
dc.subject.eng.fl_str_mv	Ovary carcinoma Type I-II tumors p53 signature TP53
publishDate	2019
dc.date.accessioned.none.fl_str_mv	2019-07-01 13:32:08 2022-06-29T19:37:50Z
dc.date.issued.none.fl_str_mv	2019-07-01
dc.date.available.none.fl_str_mv	2019-07-01 13:32:08 2022-06-29T19:37:50Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v28.n2.2019.918
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2916
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v28.n2.2019.918
identifier_str_mv	10.31260/RepertMedCir.v28.n2.2019.918 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2916 https://doi.org/10.31260/RepertMedCir.v28.n2.2019.918
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol. 2017;3(4):524. 2. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420–32. 3. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004 May;164(5):1511–8. 4. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. 5. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433–43. 6. Hernández D, González Y. Carcinomas epiteliales del ovario de alto y bajo grado. Repert.med.cir2. 2015;24(2):105–12. 7. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):995–1005. 8. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006 Feb;30(2):230–6. 9. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451–6. 10. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb;31(2):161–9. 11. Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT. Role of Fallopian Tubes in the Development of Ovarian Cancer. J Minim Invasive Gynecol. 2017 Feb;24(2):230–4. 12. Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, Ó hAinmhire E, Modi DA, et al. Mutant p53 expression in fallopian tube epithelium drives cell migration. Int J Cancer. 2015 Oct 1;137(7):1528–38. 13. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–15. 14. Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao D-F, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005 Feb;29(2):218–24. 15. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011 Sep;24(9):1248–53. 16. Kurman, R.J., Carcangiu, M.L., Herrington, C.S., Young RH. WHO Classification of Tumours. IARC WHO Classification of Tumours. 2014. 17. Munakata S, Yamamoto T. Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan. Int J Gynecol Pathol. 2015 Jan;34(1):9–18. 18. Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011 Dec;35(12):1766–75. 19. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004 Jan;23(1):35–40. 20. Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics. 2011;66(1):73–6. 21. Piek JMJ, Verheijen RHM, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003 Aug;90(2):491. 22. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Tubal ligation and risk of ovarian cancer. Lancet (London, England). 2001 Sep 8;358(9284):844. 23. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009 Apr;3(2):165–70. 24. Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn L-C. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011 Sep;30(5):417–24. 25. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007 Jan;211(1):26–35. 26. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005 Dec;106(6):1327–34. 27. Min K-W, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, et al. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 2013 Jan;32(1):3–14. 28. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 2014 Mar;64(4):585–96. 29. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007 Jun;103(2):225–32. 30. Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN,
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/991 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1012 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1025 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1038 https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1051
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2019 : Mayo - Agosto
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationvolume.spa.fl_str_mv	28
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	application/pdf text/html application/xml application/epub+zip audio/mpeg
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/918
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/296bed0e-4d79-46d2-839e-c4e2837379d1/download
bitstream.checksum.fl_str_mv	aea8875791893ad7d6476e2916b7814f
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1811575296636223488
spelling	Parra Medina, Rafael4c7838d301e82a78f94699bdd84bbf42500Yaspe, Edgardo37c82cc3e08aceaf83c637e73dc53e53500Hernández, Diana2281287b86e5f6fad54d5236ccf13915Sánchez, Diana Marcela9e26a569f890a0ea9efc3c347622b40c300Marulanda, Lina377db4ebc39d32fd85341db38918cff5300Polo, José Fernando26a307d65d1ae934f3debd994814a2095002019-07-01 13:32:082022-06-29T19:37:50Z2019-07-012019-07-01 13:32:082022-06-29T19:37:50ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/918Carcinoma de ovarioTumores tipo I-IIp53 signatureTP53Ovary carcinomaType I-II tumorsp53 signatureTP53Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.Ovary and fallopian tube expression of p53 in primary epithelial ovarian cancerapplication/pdftext/htmlapplication/xmlapplication/epub+zipaudio/mpegArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v28.n2.2019.9180121-7372https://repositorio.fucsalud.edu.co/handle/001/29162462-991Xhttps://doi.org/10.31260/RepertMedCir.v28.n2.2019.918spaFitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncol. 2017;3(4):524. 2. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug;43(5):420–32. 3. Shih I-M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004 May;164(5):1511–8. 4. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. 5. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433–43. 6. Hernández D, González Y. Carcinomas epiteliales del ovario de alto y bajo grado. Repert.med.cir2. 2015;24(2):105–12. 7. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20;26(6):995–1005. 8. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006 Feb;30(2):230–6. 9. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451–6. 10. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb;31(2):161–9. 11. Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT. Role of Fallopian Tubes in the Development of Ovarian Cancer. J Minim Invasive Gynecol. 2017 Feb;24(2):230–4. 12. Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, Ó hAinmhire E, Modi DA, et al. Mutant p53 expression in fallopian tube epithelium drives cell migration. Int J Cancer. 2015 Oct 1;137(7):1528–38. 13. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–15. 14. Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao D-F, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005 Feb;29(2):218–24. 15. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011 Sep;24(9):1248–53. 16. Kurman, R.J., Carcangiu, M.L., Herrington, C.S., Young RH. WHO Classification of Tumours. IARC WHO Classification of Tumours. 2014. 17. Munakata S, Yamamoto T. Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan. Int J Gynecol Pathol. 2015 Jan;34(1):9–18. 18. Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011 Dec;35(12):1766–75. 19. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004 Jan;23(1):35–40. 20. Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics. 2011;66(1):73–6. 21. Piek JMJ, Verheijen RHM, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003 Aug;90(2):491. 22. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Tubal ligation and risk of ovarian cancer. Lancet (London, England). 2001 Sep 8;358(9284):844. 23. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009 Apr;3(2):165–70. 24. Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn L-C. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol. 2011 Sep;30(5):417–24. 25. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007 Jan;211(1):26–35. 26. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005 Dec;106(6):1327–34. 27. Min K-W, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, et al. Clear cell carcinomas of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 2013 Jan;32(1):3–14. 28. Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor. Histopathology. 2014 Mar;64(4):585–96. 29. Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007 Jun;103(2):225–32. 30. Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN,https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/991https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1012https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1025https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1038https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/918/1051Núm. 2 , Año 2019 : Mayo - Agosto228Revista Repertorio de Medicina y Cirugíainfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2PublicationOREORE.xmltext/xml2943https://repositorio.fucsalud.edu.co/bitstreams/296bed0e-4d79-46d2-839e-c4e2837379d1/downloadaea8875791893ad7d6476e2916b7814fMD51001/2916oai:repositorio.fucsalud.edu.co:001/29162024-02-02 13:06:58.658https://creativecommons.org/licenses/by-nc-sa/4.0/metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Expresión de p53 en ovario y trompa uterina de tumores malignos epiteliales primarios del ovario.

Publicaciones similares